Related by context. All words. (Click for frequent words.) 78 orally administered inhibitor 75 PNP inhibitor 74 vascular disrupting agents 74 sodium glucose cotransporter 73 PDE4 inhibitor 73 JAK2 inhibitor 73 Panzem R 73 Personalized Immunotherapy 73 IAP inhibitor 72 oral prodrug 72 investigational humanized monoclonal antibody 72 Aurora kinase 72 ENMD # 72 targeting CD# 72 humanized anti 72 Solazed TM 72 FGFR 72 pan HDAC inhibitor 71 selective inhibition 71 2 inhibitor CYT# 71 MEK inhibitor 71 Janus Kinase 71 hypoxia inducible factor 71 mGluR5 negative 71 IAP inhibitors 71 novel VDA molecule 71 myeloproliferative disorders 71 Xanafide 71 RNAi therapeutic targeting 71 selective immunoproteasome inhibitor 71 JAK inhibitors 70 HCV protease 70 multi kinase inhibitor 70 mertansine 70 ARRY # 70 small molecule defensin 70 VEGF receptors 70 PEGylated Fab fragment 70 CYC# 70 investigational pan BCR 70 CCR2 70 HDACi 70 phosphate S1P 70 Panzem R NCD 70 RNA antagonist 70 CCR9 antagonist 70 2 methoxyestradiol 70 CYT# potent vascular disrupting 70 MEK inhibitors 70 vidofludimus 70 Factor VIIa 70 polymerase inhibitor 70 Symadex 70 liposomal formulation 70 isoform selective 70 HSP# inhibitor 70 antibody MAb 70 selective kinase inhibitor 69 Ophthotech 69 targeted radiotherapeutic 69 drug pipeline TAFA# 69 histone deacetylase 69 G Protein Coupled 69 5 HT6 69 apoptosis proteins 69 Squalamine 69 Aurora Kinase 69 TKM ApoB 69 chemokine receptor 69 nicotinic alpha 7 69 HCV protease inhibitor 69 humanized monoclonal 69 INCB# [003] 69 tiapamil 69 OXi# 69 Janus kinase 69 PDX pralatrexate 69 CCX# 69 Aflibercept 69 Preclinical studies suggest 69 antisense oligonucleotide 69 myelofibrosis polycythemia vera 69 potent inhibitor 69 TLR9 agonist 69 selective modulator 69 MTP inhibitor 69 CD3 monoclonal antibody 69 Thiarabine 69 PEG SN# 69 anti CD3 69 AEG# 69 VitiGam 69 A3 adenosine receptor 69 CORT # 69 JAK#/JAK# 69 ABL inhibitor 69 humanized monoclonal antibody 68 XmAb# 68 TKB# 68 ALN TTR 68 CTAP# Capsules 68 sodium thiosulfate STS 68 vascular disrupting agent 68 P#X# 68 proteasome inhibitor 68 huC# DM4 68 candidate deforolimus 68 novel peptide 68 SGLT2 68 orally bioavailable 68 IRX 2 68 telomerase therapeutic 68 Hsp# Inhibitor 68 histone deacetylase HDAC inhibitor 68 ganetespib 68 c Raf kinase 68 Archexin 68 non nucleoside inhibitor 68 HQK 68 N acetylgalactosamine 6 68 XL# XL# 68 Tezampanel 68 Hybridon 68 Hsp# inhibition 68 alpha folate receptor 68 IMC #B 68 novel histone deacetylase 68 antisense oligonucleotides 68 small molecule inhibitors 68 polymerase inhibitors 68 TRO# 68 receptor tyrosine kinase inhibitor 68 NPC 1C 68 metaglidasen 68 Tyrima 68 anticancer compound 68 oral JAK1 68 HDAC Inhibitor 68 Vascular Endothelial Growth 68 Factor Receptor 68 targeted antifolate 68 JAK inhibitor 68 CDK inhibitor 68 HuLuc# 68 delta isoform 68 XL# anticancer compounds 68 Sym# 68 TLK# 68 FOLOTYN ® 68 protein tyrosine phosphatase 1B 68 Omacetaxine 68 Tumour Vascular Disrupting Agent 68 Locked Nucleic Acid 68 AtuRNAi 68 Guanilib 68 chemokine receptors 68 mTOR mammalian target 68 CD# CEA 68 histone deacetylase HDAC 68 mitogen activated ERK kinase 67 PXD# 67 VEGF inhibitors 67 Kinase Inhibitor 67 AAG geldanamycin analog 67 bevacizumab Avastin ® 67 Phase #b/#a clinical 67 VEGF receptor 67 CD# antibody [001] 67 Hsp# inhibitors 67 Phase Ib study 67 hematological cancers 67 histone deacetylase inhibitor 67 small molecule thrombopoietin 67 oxidative stress inducer 67 radiation sensitizer 67 tubulin inhibitor 67 Presents Preclinical Data 67 pharmacological chaperone 67 polysaccharide polymer 67 PSN# [002] 67 ErbB3 67 oral picoplatin 67 Phase 2b Clinical Trial 67 INCB# [001] 67 small molecule activator 67 sodium glucose transporter 67 Sapacitabine 67 ALN PCS 67 depsipeptide 67 ATL# [001] 67 Annamycin 67 OMP #R# 67 CA4P 67 epothilone 67 partial agonist 67 cMET 67 ADP receptor antagonist 67 antibody MT# 67 Tesetaxel 67 essential thrombocythemia ET 67 PS# [001] 67 poly ADP ribose polymerase 67 JAK3 67 cyclin dependent kinase inhibitor 67 molecular imaging radiopharmaceutical 67 allosteric modulator NAM 67 MKC# MT 67 acetonide FA 67 adenoviral 67 Hedgehog pathway inhibitor 67 FLT3 67 immunosuppressive compound 67 PI3K/mTOR 67 IMA# 67 NS4A 67 Histone Deacetylase 67 KSP inhibitor 67 reversible inhibitor 67 ATL# [002] 67 Immunotherapeutic 67 cetuximab Erbitux R 67 antisense inhibitors 67 MET VEGFR2 67 Phase IIb trials 67 MGCD# [001] 67 HGS ETR1 67 drug conjugate 67 cell adhesion molecule 67 PI3K/Akt pathway inhibitor 67 p# mitogen activated 67 ocular formulation 67 Randomized Phase 67 dasatinib Sprycel ® 67 Aurora kinase inhibitor 67 sphingosine 1 67 selective antagonist 67 VEGFR2 inhibitor 67 BiTE antibody 67 tyrosine kinase inhibitor 67 refractory chronic lymphocytic 67 kidney urologic 67 Bezielle 67 Hsp# inhibitor 67 SinuNase TM 67 registrational trial 67 agonist compounds 67 Exelixis compounds 67 OMP #M# 67 small molecule inhibitor 67 chronic eosinophilic leukemia 67 TRX1 67 familial amyloidotic polyneuropathy FAP 67 novel topoisomerase 67 selective androgen receptor modulator 67 kinase inhibitor 67 Glufosfamide 67 Talabostat 67 beta 1a 67 RhuDex ® 67 Litx 67 ELACYT 67 RGB # 67 developing Bicifadine serotonin 67 Curaxins 66 AMPA kainate 66 selective inhibitor 66 lintuzumab SGN 66 GMX# 66 JAK2 66 alvespimycin 66 receptor partial agonist 66 aurora kinase 66 oral proteasome inhibitor 66 PDGFR 66 highly selective inhibitor 66 Atiprimod 66 entinostat 66 Dapagliflozin 66 allosteric modulator 66 thrombin receptor 66 volociximab 66 cancer immunotherapies 66 HCD# [002] 66 investigational compounds 66 TLR9 agonists 66 angiogenesis inhibitor 66 virus HCV protease inhibitor 66 CD# expressing 66 CBLC# 66 TRAIL receptor 66 siRNA therapeutic 66 antisense drug 66 EGFR HER2 66 Azedra 66 anticancer compounds 66 Factor VEGF 66 Plicera 66 Initiate Phase 66 immunomodulatory 66 ALN TTR# 66 MKC# MKC# PP 66 Ocrelizumab 66 HuMax EGFr 66 Ceflatonin R 66 Inhaled AAT 66 AQ4N 66 Traficet EN 66 dasatinib Sprycel 66 therapeutic monoclonal antibody 66 signal transduction inhibitor 66 M2 subunit 66 IL #E 66 YONDELIS 66 CCR5 antagonist 66 ALN HPN 66 HGS# 66 CD# monoclonal antibody 66 PDE# 66 Sphingomab 66 DNA methyltransferase inhibitors 66 NXL# 66 Eg5 66 drug ISA# 66 Fc fusion protein 66 Phase 2a Clinical Trial 66 Pathway Inhibitor 66 stable nucleic acid 66 humanized antibody 66 Palifosfamide 66 Onconase 66 epigenetic therapies 66 generation purine nucleoside 66 Nanobody 66 TELINTRA 66 novel immunomodulatory 66 maturation inhibitor 66 PRT# 66 Orally administered 66 TLR7 66 talactoferrin 66 investigational monoclonal antibody 66 product platforms AZX# 66 Phase 1b clinical trials 66 Aplidin 66 fosbretabulin 66 anti fibrotic 66 exon skipping 66 Phase Ib clinical trials 66 P#X# antagonist 66 bevacizumab Avastin R 66 selective adenosine 66 uricase 66 Exherin 66 DDP# 66 diarrhea predominant irritable 66 Carfilzomib 66 EGFr 66 small molecule tyrosine 66 otelixizumab 66 cell lymphoma CTCL 66 thymidylate synthase TS 66 LymphoStat B TM 66 SARMs 66 VEGFR 66 Alfacell proprietary ribonuclease 66 MDV# 66 PDGF receptor 66 RON Notch 66 delafloxacin 66 humanized monoclonal antibodies 66 DOS# 66 targets Galectin receptors 66 irreversible inhibitor 66 Romidepsin 66 inhibitor RG# 66 Lixivaptan 66 methionine aminopeptidase 66 lysophosphatidic acid LPA 66 Reports Preclinical Data 66 Epidermal Growth Factor Receptor 66 Telatinib 66 relapsed leukemia 66 IL# PE#QQR 66 Azedra TM 66 IgG1 antibody 66 Nanobody ® 66 PRTX 66 MT# MEDI 66 SPRYCEL ® 66 XL# XL# XL# XL# 66 trastuzumab Herceptin R 66 highly selective adenosine 66 PLK1 SNALP 66 TRAIL Receptor 66 huN# DM1 66 anti CD3 monoclonal 66 Pralatrexate 66 somatostatin analogue 66 preclinically 66 kinase inhibition 66 AzaSite Plus 65 Ridaforolimus 65 ESBA# 65 NS#/#A protease 65 antiproliferative effects 65 IMiD 65 vesicular monoamine transporter 65 atacicept 65 GW# [003] 65 siRNA therapeutics 65 immatics 65 JZP 65 small molecule agonists 65 #ME# 65 MAGE A3 ASCI 65 oral Hsp# inhibitor 65 forodesine 65 AzaSite Xtra 65 Bortezomib 65 c MET 65 CCR9 65 PKC# 65 Recombinant Human 65 Onalta ™ 65 TG# [003] 65 induce apoptosis 65 CEQ# 65 anticancer agent 65 Cannabinor 65 essential thrombocythemia 65 immune stimulatory 65 ErbB 65 HuMax CD4 65 romazarit 65 Akt inhibitor 65 hypereosinophilic syndrome 65 oral nucleoside analogue 65 IMC A# 65 rxRNA 65 delivered RNAi therapeutic 65 Curaxin CBLC# 65 THR beta agonist 65 sunitinib Sutent ® 65 erlotinib Tarceva ® 65 Fludara ® 65 HspE7 65 dextromethorphan quinidine 65 specific lectin receptors 65 potent antiproliferative 65 LymphoStat B belimumab 65 HGS ETR2 65 Elvitegravir 65 TRIOLEX 65 Hedgehog Pathway Inhibitor 65 Protein Kinase C 65 KL4 Surfactant 65 Symphogen 65 Tumor Necrosis Factor 65 imatinib Gleevec ® 65 TRAIL R2 65 ruxolitinib 65 phase IIb clinical 65 Sudhir Agrawal D.Phil 65 Angiocept 65 R#/MEM # 65 Perifosine 65 accumulate preferentially 65 seliciclib CYC# 65 NS5A 65 SERMs 65 RNAi therapeutic 65 antibody fragment 65 Proxinium TM 65 Luteinizing Hormone Releasing Hormone 65 EZN 65 hypoxia activated prodrug 65 serine protease 65 CYP#A# CYP#D# 65 HGS ETR1 mapatumumab 65 Hedgehog signaling pathway 65 Hsp# chaperone system 65 Virulizin ® 65 OvaRex R 65 pro angiogenic 65 Shigamabs ® 65 compound AEZS 65 reversible inhibitors 65 Silodosin 65 immunomodulator 65 MT#/MEDI-# 65 HDAC inhibitor 65 immunostimulatory 65 Igeneon 65 Rigel R# 65 mRNA antagonists 65 Angiotensin Converting Enzyme 65 Fleximer 65 ATL/TV# 65 histone deacetylase HDAC inhibitors 65 PI3K inhibitor 65 Aviptadil 65 Ras MAPK pathway 65 PEGylated 65 OMNARIS HFA 65 BiTE R 65 TACI Ig 65 EOquin 65 PTP 1B 65 #beta HSD1 65 Solazed ™ 65 Alocrest 65 Systemic Delivery 65 Chemokine Receptor 65 GVAX ® 65 SinuNase ™ 65 elotuzumab 65 Xyfid TM 65 soluble tumor necrosis 65 5 HT2A inverse 65 deforolimus 65 compound PMX # 65 Completes Patient Enrollment 65 HCV polymerase inhibitors 65 Elagolix 65 TTR gene 65 Avicena 65 generation antisense inhibitor 65 OncoVEX GM CSF 65 IMiDs R 65 peripherally restricted 65 hematological malignancies 65 CR# vcMMAE 65 Phase IIb clinical trials 65 Alnylam #x# 65 Lenocta 65 CD4 monoclonal antibody 65 eniluracil 65 immunomodulating 65 Mipomersen 65 TÎ ² 4 65 Monoclonal Antibody 65 Metastatic Melanoma 65 selective agonist 65 GKAs 65 vinca alkaloid 65 mGluR2 positive 65 Tarvacin TM 65 miR #a [002] 65 ASONEP 65 replicon 65 TRAIL receptor antibodies 65 oncolytic vaccine 65 alagebrium 65 Vascugel 65 leukemia AML 65 HIV integrase inhibitors 65 kinesin spindle protein KSP 65 CRTH2 65 Transfection Reagent 65 defensin mimetic antibiotic 65 Advanced Renal Cell 65 castrate resistant prostate cancer 65 BiTE 65 potently inhibit 65 including eniluracil ADH 65 Hypoxia Inducible Factor 65 Galectin 65 Etubics 65 small molecule Hedgehog 65 Azixa 65 selective inhibitors 65 OTCBB PYTO 65 intranasal formulation 65 REGENERX BIOPHARMACEUTICALS INC. 65 imatinib Gleevec 65 Familial Adenomatous Polyposis FAP 65 vaccine GRNVAC1 65 mitotic kinesin 65 Intravenous CP 64 RNA antagonists 64 sapropterin dihydrochloride 64 therapeutic monoclonal antibodies 64 JAK2 Inhibitor 64 AT1R 64 MEK inhibitor RDEA# 64 receptor agonists 64 XL# inhibits 64 potent inhibition 64 OHR/AVR# 64 Antitumor Activity 64 octreotide implant 64 agonistic human 64 adecatumumab MT# 64 trastuzumab DM1 T DM1 64 R roscovitine 64 zanolimumab 64 5 HT2A serotonin 64 RNAi therapeutic targeting PCSK9 64 engineered RAP peptides 64 Exherin TM 64 induces apoptosis 64 selective orally bioavailable 64 adhesion molecule 64 immunomodulation 64 reslizumab 64 Phase 2a trial 64 PNT# 64 Pimavanserin 64 delivers fluocinolone acetonide FA 64 MLN# 64 mu opioid receptor antagonist 64 oncology therapeutics 64 Vidofludimus 64 ALK inhibitor 64 Genasense ® oblimersen 64 CINOD 64 PrevOnco 64 NTDDS 64 Disease IBD 64 cutaneous T 64 Tyrosine Kinase Inhibitor 64 cathepsin K inhibitor 64 rusalatide acetate 64 Enkephalin 64 rALLy clinical trial 64 Posiphen 64 investigational immunotherapy 64 non nucleoside polymerase 64 systemic anaplastic large 64 trial evaluating PRX# 64 TO AVOID PREGNANCY WHILE 64 5 HT6 receptor 64 immunoregulatory 64 Phase #b/#a trial 64 evaluating satraplatin 64 cyclin dependent kinases CDKs 64 anti CD# antibodies 64 Gleevec resistant 64 Pervasis 64 Dicer Substrate Technology 64 biologic therapeutics 64 novel anticancer 64 interleukin IL 64 Present Preclinical Data 64 Amigal 64 ABLYNX 64 Seliciclib 64 CDK cyclin dependent 64 p# inhibitor 64 pertuzumab 64 CCR1 64 SIRT2 64 prokinetic agent 64 Voreloxin 64 NS5b 64 YONDELIS R 64 Receptors GPCRs 64 fusion proteins 64 inhaled formulation 64 glucagon receptor 64 PEGylated anti 64 antiproliferative activity 64 FOLFOX6 chemotherapy regimen 64 TLR8 agonist 64 HDAC 64 oral ghrelin agonist 64 non nucleoside HCV 64 IgG1 monoclonal antibody 64 antiangiogenesis therapies 64 Enzastaurin 64 CTLA 4 64 Leukine ® 64 Epratuzumab 64 polyglutamate 64 BXT # 64 Ozarelix 64 anticancer therapeutics 64 Synavive 64 polycythemia vera PV 64 Apoptone 64 Scancell 64 Meets Primary Endpoint 64 pan histone deacetylase 64 proteasome inhibitors 64 hormone gastrin 64 DGAT 64 clinically validated targets 64 antisense inhibitor 64 Spiegelmer ® 64 Bafetinib 64 antisense drugs 64 Harbor BioSciences 64 regulated kinase 64 XmAb ™ 64 induced macular edema 64 CORLUX CORT # 64 bexarotene 64 ALN VSP 64 PSMA ADC 64 Iluvien ® 64 SIRT1 activators 64 immunotherapeutic 64 Novolimus 64 promoter methylation 64 HER1 64 Microplasmin 64 XmAb 64 AKT inhibitor 64 #D#C# 64 nucleoside analog 64 SGLT inhibitors 64 Pivotal Phase 64 HTS assay 64 chimeric monoclonal antibody 64 Anavex #-# 64 Anticalin ® 64 VTAs 64 5 HT2C 64 oncolytic 64 cetuximab Erbitux ® 64 Intarcia 64 Bruton tyrosine kinase 64 Æterna Zentaris 64 bone morphogenic protein 64 adult mesenchymal stem 64 Phase 2b Trial 64 LEUKINE 64 novel RNAi therapeutics 64 preclinical compounds 64 OncoGel 64 5 lipoxygenase 64 selectively inhibits 64 PI3 kinase 64 proto oncogene 64 ApoB SNALP 64 Flt3 64 investigational HCV polymerase 64 EndoTAG 64 Nanobodies 64 mGluR4 64 DiLA2 64 Chemokine 64 TAFA# 64 NEUGENE 64 Phase IIb Clinical Trial 64 MCSP respectively 64 Initiates Phase II 64 Fibroblast Growth Factor Receptor 64 Radiation Therapy SIRT 64 antisense inhibition 64 TBC# 64 AEGR 64 hyaluronidase enzyme 64 thiazolides 64 vaccines oncolytic virus 64 Successfully Completes Phase 64 PANVAC VF 64 Blinatumomab 64 oncolytic virotherapy 64 seliciclib 64 INCB# [002] 64 Chemokine Therapeutics 64 Celator 64 Novosom 64 Anticalin R 64 SAR# [002] 64 Interferon alpha 64 Quinamed 64 Aplidin R 64 Triapine 64 TLR9 64 secretory phospholipase A2 sPLA2 64 MGd 64 bispecific antibody 64 epothilones 64 HepDirect 64 Hedgehog pathway 64 BAY #-# 64 ZP# [002] 64 DNA intercalator 64 B lymphocyte stimulator 64 Ceflatonin 64 modified glutathione analog 64 Novel Oral 64 OTCBB HXBM developer 64 pathophysiological effects 64 HuMax 64 Phase Ib Clinical Trial 64 Inc. NASDAQ IDMI 64 peptidomimetic 64 geldanamycin 64 ANG# 64 Epothilones 64 milatuzumab 64 5 HT4 64 glucokinase activator 64 LE SN# 64 cilengitide 64 EGF receptor 64 herpetic keratitis 64 Cetrorelix 64 GRN# 64 Cutaneous T 64 generation nucleoside analog 64 Humanized Anti 64 Aganocide ® 64 BZL# 64 DPX Survivac 64 lymphoid malignancies 64 transient receptor 63 Chemophase 63 colorectal carcinoma 63 receptor inhibitor 63 myeloproliferative diseases 63 TPI ASM8 63 cytotoxic T lymphocyte 63 Troxatyl 63 relapsed acute myelogenous 63 Neogenix 63 peptibody 63 humanized antibodies 63 Locked Nucleic Acid LNA 63 acadesine 63 BCR ABL 63 TNF Tumor Necrosis Factor 63 APOPTONE 63 urocortin 2 63 novel synthetic peptide 63 oral taxane 63 xenograft models 63 LHRH receptor positive 63 T#I [002] 63 anticancer agents 63 Pruvel 63 TRIOLEX ™ 63 chemically modified siRNA 63 mTOR inhibitor 63 pediatric acute lymphoblastic 63 Allovectin 7 R 63 catheter occlusion 63 delta opioid receptor 63 miR #a [001] 63 activin receptor type 63 Anticalins R 63 MOZOBIL 63 TYZEKA 63 adipogenic 63 NASDAQ SNTA 63 immunotherapeutics 63 XL# XL# XL# 63 Receptor Antagonists 63 Tarceva TM 63 telomerase inhibitor drug 63 platinum chemotherapeutic 63 obatoclax 63 ulimorelin 63 Intravenous Human 63 PPARgamma 63 small molecule glucokinase 63 5 HT4 receptor 63 R roscovitine CDK cyclin 63 certain protein tyrosine 63 lexidronam injection 63 radezolid 63 TLR8 63 CB2 selective receptor agonist 63 Elotuzumab 63 5 HT2A receptor 63 VEGFR2 63 Antisense 63 cytokines IL 63 Aganocide 63 PI3K inhibitors 63 3 kinase PI3K 63 NNRs 63 Aurexis R 63 orally bioavailable mimics 63 PHX# 63 FGFR3 63 generation Hsp# inhibitor 63 Androgen Receptor 63 anti CTLA 63 UsiRNAs 63 PI3K Akt 63 renin inhibitors 63 ZYBRESTAT TM 63 selectively inhibit 63 oral Factor Xa 63 proprietary polysaccharide 63 include PLX IBD 63 BHT DNA 63 compound perifosine 63 dacetuzumab SGN 63 MyVax ® 63 Nasdaq HALO 63 Vascular Disrupting Agent 63 Azacitidine 63 InterfeRx 63 immunotoxin 63 Cintredekin Besudotox 63 PEGylated interferon beta 1a 63 GRNVAC1 63 Wnt signaling pathway 63 OGeS 63 Pharmion Corporation 63 LPA1 receptor 63 Catalyst Biosciences 63 HDL Mimetic Peptide 63 selective GR 63 rhIL 7 63 ERK pathway 63 transthyretin mediated amyloidosis ATTR 63 triciribine phosphate monohydrate 63 acyclovir Lauriad R 63 proliferative diseases 63 Myelodysplastic Syndrome MDS 63 AVN# [001] 63 INT# [002] 63 immune modulatory 63 formerly LymphoStat B 63 Polymer Microspheres 63 renin inhibitor 63 GLP toxicology studies 63 mediated apoptosis 63 CRMD# 63 IMiDs ® compound 63 tiuxetan 63 5 hydroxytryptamine 63 StemEx 63 tyrosine kinase receptor 63 Zenvia ™ 63 Sphingomab TM 63 II Clinical Trial 63 peripherally acting 63 epithelial tumors 63 FBPase 63 OMNARIS Nasal Spray 63 MNTX 63 thalidomide Thalomid 63 multikinase inhibitor 63 Degarelix 63 OMRIX Biopharmaceuticals Inc. 63 Initiates Phase 63 ATRA IV 63 NovaBay Aganocide compounds 63 Maxy G# 63 V#F mutation 63 siRNAs targeting 63 potent inhibitors 63 cyclooxygenase COX 63 NASDAQ LGND 63 Nasdaq PARD 63 peroxisome proliferator activated 63 DCVax R 63 Safinamide 63 Preclinical Data 63 docetaxel Taxotere ® 63 Nasdaq ENZN 63 Tarmogen 63 #HT#A 63 HuMax CD# 63 Tumor necrosis factor 63 candidates Azedra TM 63 Vicinium TM 63 immunotherapeutic agent 63 ISF# 63 GLP1 INT TM 63 Phase 2a clinical trials 63 abnormal p# 63 Onalta 63 transthyretin TTR mediated amyloidosis 63 mGluR2 NAM 63 Ecallantide 63 immuno inflammatory diseases 63 carcinoma HCC 63 Aganocide R 63 Evoltra ® 63 Bicifadine 63 Minapharm 63 MAb 63 tyrosine kinase inhibitor TKI 63 GSK '# 63 docetaxel Taxotere R 63 HDAC enzymes 63 cyclin dependent kinase 63 IL #p# 63 osteogenic 63 receptor agonist 63 Initiates Enrollment 63 SNALP technology 63 Upregulation 63 MMAE 63 personalized immunotherapy 63 HIV integrase inhibitor 63 Chronic Myeloid Leukemia CML 63 Vaccinex 63 SAR# [004] 63 neuropathic pain metabolic diseases 63 peptidic compound